172. 低ホスファターゼ症 Hypophosphatasia Clinical trials / Disease details


臨床試験数 : 34 薬物数 : 17 - (DrugBank : 4) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 6

  
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01406977
(ClinicalTrials.gov)
July 201129/7/2011Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP)An Open-label, Intra-patient Dose-escalation Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP).HypophosphatasiaDrug: BPS804Ultragenyx Pharmaceutical IncMereo BioPharma;NovartisCompleted18 Years70 YearsAll8Phase 2Germany
2EUCTR2010-024013-31-DE
(EUCTR)
30/06/201107/02/2011A clinical study to evaluate the safety and preliminary efficacy of BPS804 in adults with hypophosphatasiaAn open-label, intra-patient dose-escalation study to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of multiple infusions of BPS804 in adults with hypophosphatasia Hypophosphatasia (HPP) is a rare genetic metabolic disorder which results in impaired skeletal mineralization, and which is caused by the absence of or by deficient enzymatic activity of the tissue-nonspecific alkaline phosphatase (TNSALP)
MedDRA version: 14.1;Level: PT;Classification code 10049933;Term: Hypophosphatasia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Product Name: BPS804
Product Code: BPS804
Other descriptive name: fully human IgG2 lambda monoclonal antibody
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
9Germany